← Leaderboards

James L Riley

University Of Pennsylvania

Google Scholar ↗PubMed ↗ORCID ↗

$56,591,102

Attributed

$96,737,308

Total exposure

34

Grants

28

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $13.4M · FY2005–25

$20M$15M$10M$5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$125,578,670 · 37

By mechanism

UM1$53,599,846 · 2

U19$36,481,005 · 13

P01$10,487,850 · 5

R01$9,277,057 · 5

P30$4,888,101 · 5

UH3$3,372,768 · 1

Top collaborators

Most similar at University Of Pennsylvania

Same institution · by research overlap

Pablo Tebas$38,856,630
Carl H. June$35,377,952
Michael Holmes$2,416,645
Bent K Jakobsen$1,090,522
Dennis E. Discher$22,706,504

Others in their field

Top investigators on “T-Lymphocyte”

Barton F Haynes · Duke University$296,833,570
Lawrence Corey · Fred Hutchinson Cancer Center$270,341,865
Dan H. Barouch · Fred Hutchinson Cancer Center$117,305,894
Margaret Juliana McElrath · Fred Hutchinson Cancer Center$107,651,960
Alessandro Sette · La Jolla Institute For Immunology$75,756,097
Rama Rao Amara · Emory University$69,530,112

Research focus

T-LymphocyteCellsHiv-1In VivoBaseImmuneResearch PersonnelInfectionClinical TrialsImmunotherapyResponseDesignPhase I Clinical TrialsHiv InfectionsNovel StrategiesCd4 Positive T LymphocytesTechnologyImmune SystemMouse ModelEngineeringFutureLeadInnovationAntiretroviral Therapy

Grant awards (119)

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,626,081

UM1 · FY2025 · AI

Immunoengineering Durable Control of HIV Replication$3,643,653

P01 · FY2025 · AI · contact PI

Non-human Primate (NHP Core)$929,192

P01 · FY2025 · AI · contact PI

Engineering T cells to Promote Islet Transplant$771,158

R01 · FY2025 · DK · contact PI

Eliminating the latent reservoir by targeted in vivo delivery of HIV-specific CARs$758,836

R01 · FY2025 · AI · contact PI

Engineering CAR T cells to Provide a Durable Control of HIV Replication$505,417

P01 · FY2025 · AI · contact PI

Molecular & Translational Immunotechnology Core$258,908

P30 · FY2025 · AI · contact PI

Admin Core$162,500

P01 · FY2025 · AI · contact PI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,736,593

UM1 · FY2024 · AI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,369,588

U19 · FY2024 · AI · contact PI

Modeling Combination Immunotherapy for HIV Cure in Humanized Mouse Models$898,849

U19 · FY2024 · AI · contact PI

Engineering T cells to Promote Islet Transplant$774,236

R01 · FY2024 · DK · contact PI

Eliminating the latent reservoir by targeted in vivo delivery of HIV-specific CARs$718,306

R01 · FY2024 · AI · contact PI

HIV Pathogenesis, Vaccination and Cure$492,527

T32 · FY2024 · AI

Molecular & Translational Immunotechnology Core$276,732

P30 · FY2024 · AI · contact PI

Core A: Administrative$84,440

U19 · FY2024 · AI · contact PI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,780,735

UM1 · FY2023 · AI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,421,905

U19 · FY2023 · AI · contact PI

Microphysiological systems for modeling autoimmunity in type 1 diabetes$1,121,769

UH3 · FY2023 · DK

Modeling Combination Immunotherapy for HIV Cure in Humanized Mouse Models$978,042

U19 · FY2023 · AI · contact PI

Engineering T cells to Promote Islet Transplant$776,922

R01 · FY2023 · DK · contact PI

Eliminating the latent reservoir by targeted in vivo delivery of HIV-specific CARs$689,181

R01 · FY2023 · AI · contact PI

HIV Pathogenesis, Vaccination and Cure$516,516

T32 · FY2023 · AI

Immunology Core$278,465

P30 · FY2023 · AI · contact PI

Core A: Administrative$81,501

U19 · FY2023 · AI · contact PI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$5,839,685

UM1 · FY2022 · AI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,699,182

U19 · FY2022 · AI · contact PI

Microphysiological systems for modeling autoimmunity in type 1 diabetes$1,124,415

UH3 · FY2022 · DK

Modeling Combination Immunotherapy for HIV Cure in Humanized Mouse Models$974,093

U19 · FY2022 · AI · contact PI

Engineering T cells to Promote Islet Transplant$780,000

R01 · FY2022 · DK · contact PI

HIV Pathogenesis, Vaccination and Cure$500,633

T32 · FY2022 · AI

Immunology Core$262,277

P30 · FY2022 · AI · contact PI

Core A: Administrative$79,316

U19 · FY2022 · AI · contact PI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$6,099,975

UM1 · FY2021 · AI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,807,871

U19 · FY2021 · AI · contact PI

First-in-human study of two anti-SARS CoV-2 antibodies in health volunteers$1,571,599

UM1 · FY2021 · AI

Microphysiological systems for modeling autoimmunity in type 1 diabetes$1,126,584

UH3 · FY2021 · DK

Modeling Combination Immunotherapy for HIV Cure in Humanized Mouse Models$978,174

U19 · FY2021 · AI · contact PI

HIV Pathogenesis, Vaccination and Cure$500,670

T32 · FY2021 · AI

Immunology Core$263,750

P30 · FY2021 · AI · contact PI

Core A: Administrative$80,852

U19 · FY2021 · AI · contact PI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,035

UM1 · FY2020 · AI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,871,467

U19 · FY2020 · AI · contact PI

Microphysiological systems for modeling autoimmunity in type 1 diabetes$1,125,532

UG3 · FY2020 · DK

Modeling Combination Immunotherapy for HIV Cure in Humanized Mouse Models$996,589

U19 · FY2020 · AI · contact PI

HIV Pathogenesis, Vaccination and Cure$483,175

T32 · FY2020 · AI

Immunology Core$263,768

P30 · FY2020 · AI · contact PI

Core A: Administrative$81,000

U19 · FY2020 · AI · contact PI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,036

UM1 · FY2019 · AI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,177,593

U19 · FY2019 · AI · contact PI

Microphysiological systems for modeling autoimmunity in type 1 diabetes$1,141,032

UG3 · FY2019 · DK

Designing T cells to Functionally Cure HIV-1 infection$454,554

U19 · FY2019 · AI · contact PI

Immunology Core$263,380

P30 · FY2019 · AI · contact PI

Admin Core$171,544

U19 · FY2019 · AI · contact PI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,036

UM1 · FY2018 · AI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,247,142

U19 · FY2018 · AI · contact PI

Designing T cells to Functionally Cure HIV-1 infection$477,788

U19 · FY2018 · AI · contact PI

Immunology Core$245,686

P30 · FY2018 · AI · contact PI

Admin Core$183,999

U19 · FY2018 · AI · contact PI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,035

UM1 · FY2017 · AI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,951,367

U19 · FY2017 · AI · contact PI

Designing T cells to Functionally Cure HIV-1 infection$590,667

U19 · FY2017 · AI · contact PI

Targeting the Persistent HIV-1 Viral Reservoir Using Engineered T cells$463,011

R33 · FY2017 · AI · contact PI

Immunology Core$352,766

P30 · FY2017 · AI · contact PI

Admin Core$296,157

U19 · FY2017 · AI · contact PI

BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy$4,589,036

UM1 · FY2016 · AI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,316,462

U19 · FY2016 · AI · contact PI

Designing T cells to Functionally Cure HIV-1 infection$492,087

U19 · FY2016 · AI · contact PI

Targeting the Persistent HIV-1 Viral Reservoir Using Engineered T cells$471,643

R33 · FY2016 · AI · contact PI

Immunology Core$256,091

P30 · FY2016 · AI · contact PI

Admin Core$183,394

U19 · FY2016 · AI · contact PI

Engineering T cells to Provide Durable Control of HIV-1 Replication$2,335,132

U19 · FY2015 · AI · contact PI

Designing T cells to Functionally Cure HIV-1 infection$505,007

U19 · FY2015 · AI · contact PI

Targeting the Persistent HIV-1 Viral Reservoir Using Engineered T cells$480,000

R33 · FY2015 · AI · contact PI

Immunology Core$256,219

P30 · FY2015 · AI · contact PI

Admin Core$179,834

U19 · FY2015 · AI · contact PI

Restoring HIV-1 Specific T cell Immunity$312,379

R01 · FY2014 · CA · contact PI

Immunology Core$267,923

P30 · FY2014 · AI · contact PI

Targeting the Persistent HIV-1 Viral Reservoir Using Engineered T cells$237,248

R21 · FY2014 · AI · contact PI

Restoring HIV-1 Specific T cell Immunity$26,144

R01 · FY2014 · CA · contact PI

Restoring HIV-1 Specific T cell Immunity$302,718

R01 · FY2013 · CA · contact PI

Immunology$253,988

P30 · FY2013 · AI · contact PI

Novel Immune Assessment and Mouse Core$214,161

U19 · FY2013 · AI · contact PI

Targeting the Persistent HIV-1 Viral Reservoir Using Engineered T cells$199,998

R21 · FY2013 · AI · contact PI

Engineering Elite Control of HIV-1 Infection$141,149

U19 · FY2013 · AI · contact PI

Restoring HIV-1 Specific T cell Immunity$87,877

R01 · FY2013 · CA · contact PI

PD-1 signaling in T cells during chronic viral infection$497,456

P01 · FY2012 · AI · contact PI

Restoring HIV-1 Specific T cell Immunity$322,040

R01 · FY2012 · CA · contact PI

Immunology$258,886

P30 · FY2012 · AI · contact PI

Novel Immune Assessment and Mouse Core$231,935

U19 · FY2012 · AI · contact PI

Restoring HIV-1 Specific T cell Immunity$47,880

R01 · FY2012 · CA · contact PI

PD-1 signaling in T cells during chronic viral infection$499,390

P01 · FY2011 · AI · contact PI

Restoring HIV-1 Specific T cell Immunity$322,040

R01 · FY2011 · CA · contact PI

Immunology$305,024

P30 · FY2011 · AI · contact PI

Novel Immune Assessment and Mouse Core$267,026

U19 · FY2011 · AI · contact PI

PD-1 signaling in T cells during chronic viral infection$1,435,362

P01 · FY2010 · AI · contact PI

Restoring HIV-1 Specific T cell Immunity$331,481

R01 · FY2010 · CA · contact PI

Immunology$300,905

P30 · FY2010 · AI · contact PI

Novel Immune Assessment and Mouse Core$275,820

U19 · FY2010 · AI · contact PI

PD-1 signaling in T cells during chronic viral infection$1,377,325

P01 · FY2009 · AI · contact PI

Novel Immune Assessment and Mouse Core$288,667

U19 · FY2009 · AI · contact PI

Immunology$268,377

P30 · FY2009 · AI · contact PI

PD-1 signaling in T cells during chronic viral infection$1,437,555

P01 · FY2008 · AI · contact PI

Engineering Innate T Cell Resistance to HIV infection$338,327

U19 · FY2008 · AI · contact PI

Regulation of human T cell activation by the CD28 family$331,721

R01 · FY2008 · AI · contact PI

Development of tumor based antigen presenting cells$262,249

R01 · FY2008 · CA · contact PI

Core--Immunology Facility$254,956

P30 · FY2008 · AI · contact PI

Lentiviral Redirected T Cells for B Cancer Immunotherapy$148,503

R41 · FY2008 · CA · contact PI

Regulation of human T cell activation by the CD28 family$338,145

R01 · FY2007 · AI · contact PI

Engineering Innate T Cell Resistance to HIV infection$298,810

U19 · FY2007 · AI · contact PI

Lentiviral Redirected T Cells for B Cancer Immunotherapy$283,753

R41 · FY2007 · CA · contact PI

Development of tumor based antigen presenting cells$262,249

R01 · FY2007 · CA · contact PI

Regulation of human T cell activation by the CD28 family$348,245

R01 · FY2006 · AI · contact PI

Engineering Innate T Cell Resistance to HIV infection$313,707

U19 · FY2006 · AI · contact PI

Regulation of human T cell activation by the CD28 family$356,625

R01 · FY2005 · AI

Expansion of HIV infected T cells for immunotherapy$194,029

R21 · FY2005 · AI

Engineering Innate T Cell Resistance to HIV infection$145,807

U19 · FY2005 · AI

Regulation of human T cell activation by the CD28 family$356,625

R01 · FY2004 · AI

Expansion of HIV infected T cells for immunotherapy$233,773

R21 · FY2004 · AI